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Rift Valley fever (RVF) is a mosquito-borne zoonotic disease endemic to the African
continent. RVF is characterized by high rate of abortions in ruminants and hemorrhagic
fever, encephalitis, or blindness in humans. RVF is caused by the Rift Valley fever virus
(RVFV: genus Phlebovirus, family Bunyaviridae). Vaccination is the only known effective
strategy to prevent the disease, but there are no licensed RVF vaccines available for
humans. A live-attenuated vaccine candidate derived from the wild-type pathogenic
Egyptian ZH548 strain, MP-12, has been conditionally licensed for veterinary use in the
U.S. MP-12 displays a temperature-sensitive (ts) phenotype and does not replicate at
41◦C. The ts mutation limits viral replication at a specific body temperature and may
lead to an attenuation of the virus. Here we will review well-characterized ts mutations
for RNA viruses, and further discuss the potential in designing novel live-attenuated
vaccines for RVF.
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Rift Valley fever (RVF) is a mosquito-borne zoonotic infectious disease caused by Rift Valley fever
virus (RVFV), belonging to the genus Phlebovirus of the family Bunyaviridae (Schmaljohn and
Nichol, 2007). Since the ﬁrst reported RVF outbreak in Kenya in 1930s (Daubney and Hudson,
1931), RVFV has spread throughout sub-Saharan Africa, Egypt, Madagascar, and then to Saudi
Arabia and Yemen by the early 21st century (Bird et al., 2009; Ikegami, 2012). RVFV causes febrile
illness in adult ruminants, and a high rate of abortions and fetal malformations in pregnant ewes,
cattle, and goats, while infected newborn lambs develop acute fulminant hepatitis (Swanepoel
and Coetzer, 2004; Ikegami and Makino, 2011). Humans can become infected through direct
contact with body ﬂuids or aerosols derived from infected animals, though infected mosquitoes
also play an important role in amplifying RVFV among animals and humans (Pepin et al., 2010).
Antibody prevalence studies indicate that abattoir workers and farmers have a higher risk of
RVFV infection (Chambers and Swanepoel, 1980; Abu-Elyazeed et al., 1996; Olaleye et al., 1996).
Infected patients usually have a biphasic febrile illness, and less than 8% of patients develop
hemorrhagic fever, encephalitis, or retinitis, which results in 0.5 to 1.0% mortality rate (CDC,
2007; Bird et al., 2009; Ikegami and Makino, 2011). While the precise number of infected humans
remains unknown, the mortality rate among conﬁrmed RVF cases during a RVF outbreak in Saudi
Arabia was 13.9% (Madani et al., 2003; CDC, 2007). An eﬀective control of RVFV transmission
can minimize the impact of a RVF outbreak. Meanwhile, non-endemic countries need to prepare
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eﬀective countermeasures to prevent the introduction of RVFV.
In the U.S., RVFV is classiﬁed as a Risk Group 3 pathogen,
a Category A Priority Pathogen (NIAID/NIH), and an overlap
select agent [U.S. Department of Health and Human Services
(HHS) and Agriculture (USDA)]. Vaccination is one of the most
eﬀective approaches to minimize the spread of RVFV (Ikegami
and Makino, 2009). Since 1950s, a live-attenuated Smithburn
vaccine has been used in Africa (Grobbelaar et al., 2011). The
vaccine, however, causes abortions in pregnant ruminants, and
retains neurovirulence in non-human primates (Morrill and
Peters, 2003; Botros et al., 2006). Despite the limitations in
safety, the Smithburn vaccine had been used in Africa for RVF
prevention. In the U.S., during 1980s, the live-attenuated MP-12
vaccine was developed (Caplen et al., 1985; Ikegami and Makino,
2009). Though the MP-12 vaccine is conditionally licensed for
veterinary use in the U.S., a few studies indicated that the vaccine
may cause abortions in pregnant ewes andmild hepatitis in calves
(Hunter et al., 2002; Miller et al., 2015). It remains unknown
whether the MP-12 vaccine can replicate at an internal body
temperature in ruminants (38–39◦C), and whether vaccination
may lead to a disease associated with MP-12 replication. In
this minireview, we will describe current understandings of
temperature-sensitivity (ts) for RVFV, and summarize ts mutants
of other RNA viruses.
Life Cycle for RVFV
Rift Valley fever virus has a tripartite negative-stranded RNA
genome designated Small (S)-, Medium (M)-, and Large (L)-
segments. The S-segment encodes two open reading frames
(ORF) for a nucleoprotein (N) and a non-structural protein
(NSs) in an ambi-sense manner. TheM-segment encodes a single
ORF for a polyprotein precursor. The precursor protein is co-
translationally cleaved into four diﬀerent proteins: Gn, Gc, 78-kD
protein, and a non-structural protein (NSm). The L-segment
encodes a single ORF for the RNA-dependent RNA polymerase
(L) protein.
DC-SIGN, dendritic cell speciﬁc intercellular adhesion
molecule-3-grabbing non-integrin, is a receptor for RVFV and
binds to oligosaccharides attached to virions (Lozach et al.,
2011). After viral attachment, viral entry occurs via caveola-
mediated endocytosis in a pH-dependent manner (Harmon et al.,
2012). Upon uncoating, the L protein, derived from incoming
virions begins viral mRNA synthesis (primary transcription).
The viral polymerase cleaves a capped host mRNA, near the
5′ terminus, and uses it to prime the synthesis of viral mRNA
(cap-snatching) (Schmaljohn and Nichol, 2007). As soon as
viral proteins accumulate, the viral RNA genome becomes
encapsidated with N protein and forms the ribonucleocapsid
(RNP), which is used for RNA genome replication. The viral
envelope proteins, Gn and Gc, play a role in viral assembly. Gn
encodes a Golgi retention motif (Gerrard and Nichol, 2002),
while Gc localizes to the ER, when Gn is not present. The
complexes of Gn and Gc localize to the Golgi and trigger the
assembly of RNP and L, and then the budding of virions (Piper
et al., 2011).
Rift Valley fever virus encodes two non-structural proteins,
NSs and NSm. Both proteins are dispensable for viral replication.
However, NSs serves as a major virulence factor as it
counteracts host antiviral responses. NSs suppresses host general
transcription by interrupting the assembly of transcription factor
(TF) IIH, which is essential for the function of cellular RNA
polymerase I or II (Le May et al., 2004; Kalveram et al., 2011;
Kainulainen et al., 2014). RVFV NSs also suppresses the up-
regulation of interferon (IFN)-β promoter at a transcriptional
level by interacting with cellular transcription repressors
(Billecocq et al., 2004; Le May et al., 2008). Furthermore, RVFV
NSs promotes the degradation of dsRNA-dependent protein
kinase (PKR). PKR is a cellular sensor of dsRNA or the 5′-
triphosphate of ssRNA. Upon the binding to RNA, PKR is
dimerized. PKR homodimers then undergo autophosphorylation
and phosphorylate eukaryotic initiation factor (eIF) 2α, which
inhibits the initiation of cellular and viral translation. By
promoting the degradation of PKR, RVFV can synthesize viral
proteins without inducing signiﬁcant eIF2α phosphorylation
(Habjan et al., 2009; Ikegami et al., 2009). The minor virulence
factor, NSm, inhibits the apoptosis of infected cells, yet the lack
of NSm expression only moderately aﬀects the RVFV mortality
in mice (Won et al., 2006; Terasaki et al., 2013; Kreher et al.,
2014). The 78-kD protein and NSm contribute to an eﬃcient
dissemination of RVFV in mosquitoes (Crabtree et al., 2012;
Kading et al., 2014; Kreher et al., 2014).
RVFV ts Mutants
Rift Valley fever virus is an arbovirus and can replicate in both
mosquito and mammalian hosts in nature. RVFV can replicate
at 28◦C in insect cells (Weingartl et al., 2014), and at 41◦C
in mammalian cells (Saluzzo and Smith, 1990). Internal body
temperatures of RVFV-susceptible hosts are as follows: sheep:
38.3–39.9◦C, cattle: 38.0–39.3◦C, goats: 38.5–39.7◦C, humans:
37◦C, mice: 37.5–38.0◦C (Talan, 1984; Robertshaw, 2004). RVFV
replication initially occurs in the draining lymph nodes, liver, and
spleen (Smith et al., 2010; Gommet et al., 2011). It is important
to understand the “restrictive temperature” for the ts mutants,
because it can allow prediction of viral replication at speciﬁc body
temperatures in mammalian hosts.
Currently, little is known about ts mutations for RVF vaccine
candidates. The RVFV MP-12 strain was developed by 12 serial
plaque isolations in human lung diploid (MRC-5) cells in the
presence of a chemical mutagen, 5-ﬂuorouracil (Caplen et al.,
1985). As a result, a total of 23 mutations are encoded in the
genome: four mutations in the S-segment, nine mutations in
the M-segment, and 10 mutations in the L-segment (Figure 1).
The MP-12 vaccine does not replicate eﬃciently in vivo, though
the S-segment encodes a functional NSs gene. Saluzzo and
Smith (1990) previously characterized reassortant RVFV strains
between the pathogenic Senegal ArD38661 strain and the MP-
12 vaccine strain or the intermediate passage levels of MP-12
(MP-4, MP-6, or MP-9). Their study identiﬁed that MP-12 M-
and L-segment produce the ts phenotype. Ts mutations on the
M-segment were introduced during the MP-12 development
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FIGURE 1 | Mapping of temperature-sensitive (ts) mutations for selected
negative-stranded RNA viruses. The genome structures of RVFV MP-12
strain, Respiratory syncytial virus (RSV) cpts 248/404/1030, Influenza A virus
(MDV-A), Influenza B virus (MDV-B), and Vesicular stomatitis virus (VSV) ts114
strain are shown. Viral genes are shown in different colors: Nucleocapsid protein
(green), phosphoprotein (orange), RNA-dependent RNA polymerase (gray),
envelope protein (yellow), matrix proteins (blue), and accessory or non-structural
proteins (brown). Conserved six functional regions of RNA-dependent RNA
polymerase (RdRp) among non-segmented negative-stranded RNA viruses are
shown as I, II, III, IV, V, and VI, and those aligned to RdRp of bunyavirus and
influenza virus are also indicated. Location of representative mutations and ts
mutations (red square) are indicated by arrowheads. Putative ts mutations in the
L-segment of MP-12 are shown in green squares. For RSV mutations, the name
of clone, which encodes the mutation, is also shown in quotation.
(from 7 to 9 passages). On the other hand, ts mutation on the
L-segment occurred during the earlier stages of development (the
passage 4 or earlier). Since the U533C (V172A) and G3750A
(M1244I) mutations were introduced in the L-segment at the
passage 3, these two speciﬁc mutations may be responsible for
the ts phenotype of L-segment (Vialat et al., 1997). However, no
further characterization of ts mutations has been reported for
MP-12 vaccine.
Currently, the MP-12 vaccine is conditionally licensed in the
U.S., and themaster seed is available for the production of vaccine
lots. A number of safety and eﬃcacy tests were performed for the
MP-12 vaccine using pregnant and newborn ruminants (Morrill
et al., 1987, 1991, 1997a,b, 2013a; Morrill and Peters, 2003,
2011a,b). To understand the mechanism of attenuation for the
MP-12 vaccine, virulent recombinant ZH501 (rZH501) strains
encoding the MP-12 S-, M-, or L-segment, or a single mutation
of the MP-12 M- or L-segment were analyzed in an outbred CD1
mouse model (1 × 103 pfu, i.p) (Ikegami et al., 2015). The study
revealed that an incorporation of a MP-12 S-, M-, or L-segment
confers partial attenuation to pathogenic ZH501. Two amino
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acid changes in Gn (Y259H) and Gc (R1182G) were identiﬁed as
major attenuation mutations for the M-segment. A combination
of Y259H and R1182G only partially attenuates rZH501, while
a combination of Y259H, R1182G, plus an L-segment mutation,
G3104A (R1029K), could fully attenuate rZH501. Importantly,
MP-12 encoding reversion mutations in these three amino
acids (H259Y, G1182R, and K1029R) still retained attenuation
in mice, indicating that the attenuation of MP-12 vaccine
is supported by multiple attenuation mutations, and MP-12
does not revert into virulent phenotype by a few reversion
mutations. Further characterization of ts mutations of MP-12
vaccine will help the understanding of the mechanism behind
attenuation.
Meanwhile, Rossi and Turell (1988) isolated another ts strain
of RVFV. RVFV T1 strain was isolated from female Culex
pipiens, which fed on hamsters infected with the pathogenic
ZH501 strain. T1 strain displayed a ts phenotype at 41◦C, and
produced uniformly small plaques. The T1 strain is also highly
attenuated in hamsters, and the LD50 is >6.3 × 105 pfu (i.p).
On the other hand, the RVFV T46 strain, which was isolated
from Aedes taeniorhynchus that fed on ZH501-infected gerbils,
also predominantly produced small plaques, but was pathogenic
in hamsters, without showing a ts phenotype. As the full
genome sequences are available (T1 strain: GenBank Accession
DQ375407, DQ380201, and DQ380150, T46 strain: DQ375405,
DQ380147, and DQ380199), we analyzed the mutations that
occurred in the T1 and T46 strains compared to the parental
ZH501 strain. The T1 strain encodes two mutations in the N
gene: the G144U (G to V) mutation and a deletion of A at nt.640,
which causes a frame-shift and a premature termination of N
protein synthesis. T1 strain also encodes a mutation in the 5′-
M-untranslated region (C3818U), and two silent mutations in
the L-segment (C282U and A2691G). On the other hand, T46
strain encodes only one mutation in the M-segment (U1174A:
M to K). The T1 strain has not been further evaluated for vaccine
development.
Studies of ts Phenotype in Other RNA
Viruses
It is diﬃcult to predict viral attenuation, as a result of
mutagenesis, without using animal models. However, a ts
phenotype indicates attenuation in vivo and can be screened
for using culture cells. Ts phenotypes have been characterized
for many viruses (Richman and Murphy, 1979), using diﬀerent
approaches. In Table 1, we have summarized the ts mutants of
selected RNA viruses. The ts phenotype depends on host cell
types for the Poliovirus Sabin Type2 strain or Dengue virus NS5
gene mutants. For other RNA viruses, the majority of ts mutants
were determined by using just one or a few cell types. Thus, it
is important to broadly test diﬀerent cell types to determine a
ts phenotype. The location of ts mutations results in a unique
ts phenotype. If the viral polymerase encodes a ts mutation, the
syntheses of viral genomic RNA ormRNA, or both can be aﬀected
at a restricted temperature. If envelope proteins encode a ts
mutation, the production of infectious progeny can be ineﬃcient
at a restricted temperature. A lack of viral replication or viral RNA
synthesis can be an indicator for ts screening when a ts mutation
is encoded in the viral polymerase. On the other hand, when the ts
mutation is encoded in envelope proteins, the reduction of viral
titers may be more remarkable than the decrease in viral RNA
accumulation.
RNA-Dependent RNA Polymerase and ts
Phenotypes
Temperature-sensitive mutations have been identiﬁed in the
RNA-dependent RNA polymerases of many RNA viruses
(Table 1). Non-segmented negative-stranded RNA viruses
encode six conserved regions (Region I, II, III, IV, V, and VI) in
the RNA-dependent RNA polymerase (Rahmeh et al., 2010). The
region III (Premotif A, andMotif A, B, C, D, and E) serves in RNA
polymerization, and V and VI function in cap addition and cap
methylation, respectively. There is also an endonuclease domain
at the N-terminus of some of segmented negative-stranded RNA
viruses (Reguera et al., 2010). As described above, V172A and
M1244I mutations may be involved in the ts phenotype for MP-
12 L protein. The V172A mutation is located in Region I, while
M1244I is located downstream of Region III Motif E (Muller
et al., 1994). Though no studies have been performed for the ts
phenotype of RVFV L mutants, mutagenesis of the L protein may
identify ts mutations useful for the future rational design of RVF
vaccines. Several studies have indicated that ts phenotypes occur
from amino acid change(s) in the viral polymerase. Figure 1
illustrates the locations of ts mutations for selected negative-
stranded RNA viruses.
The vesicular stomatitis virus (VSV) ts114 mutant encodes
three amino changes (D575G, E1117G, and I1937T) in the
L-segment compared to the non-ts parental strain. The ts
phenotype occurs from D575G, which is located between
PreMotif A and Motif A in Region III (Galloway and Wertz,
2009). The ts114 mutant displayed a ts phenotype at 39◦C.
The ts114 mutant also showed a selected inhibition of viral
mRNA synthesis, while maintaining active viral RNA genome
replication. However, the selected inhibition of viral transcription
only occurred with the combination of all three mutations of
ts114, and the single D575G mutant abolished both viral genome
replication and transcription at 39◦C.
The respiratory syncytial virus (RSV) cold-adapted,
temperature-sensitive (cpts) 248/404/1030 is a live-attenuated
vaccine strain (Polack and Karron, 2004). It encodes two ts
mutations (Q831L and Y1321N) in the L region, in addition to a
nucleotide substitution in the M2 transcription start sequence.
Q831L is located between Motif C and D in Region III, while
Y1321N is located in Region V. In another study, an alanine
scan of charged amino acid residues in the RSV L protein was
performed to identify ts mutants (Tang et al., 2002). Alanine
scanning identiﬁed three types of L phenotypes: (1) Abolished L
activity, (2) Little change in L activities, and (3) a ts phenotype
at 39◦C: K157A-D158A (Upstream of Region I), E510A-R511A,
R520A, L587A-R588A, R588A-D589A (Region II and upstream)
or E1208A-R1209A (Region V).
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TABLE 1 | Determination of temperature-sensitive (ts) phenotypes for RNA viruses.
Classification Species ts strains Location of ts
mutation
Restrictive Temp for
ts (Permissive)
Cell type Reference
Family Bunyaviridae
Genus Phlebovirus RVFV MP-12 M- and L-segments 41◦C (35◦C) Vero Rossi and Turell (1988)
T1 Unknown 41◦C (35◦C) Vero Rossi and Turell (1988)
UUKV S23 ts6, 7, 8,
11, 12
Unknown 39◦C (33◦C) CEF Gahmberg (1984)
Genus Orthobunyavirus MAGV MAG ts8 M-segment 38◦C (33◦C) BHK-21 Pollitt et al. (2006)
LACV RFC/25B.5 Unknown 39.8◦C (37◦C) BHK-21 Endres et al. (1990)
BUNV rBUNdelNSs with N
mutation
N protein 38◦C (33◦C) VeroE6 Eifan and Elliott (2009)
SSHV ts1, 2, 3 Unknown 39.5◦C (33◦C) BHK-21 Gentsch and Bishop (1976)
AKV OBE-1 strain
mutants
M- and/or
L-segments
40◦C (33◦C) HmLu-1 Ogawa et al. (2007)
Family Paramixoviridae
Genus Pneumovirus RSV rA2 cpts 248/404 M2 and L 37◦C (32◦C) Hep-2 Whitehead et al. (1998)
rA2 cpts
248/404/1030
M2 and L 36◦C (32◦C) Hep-2 Whitehead et al. (1998)
Genus Respirovirus HPIV3 rHPIV3 JS cp45 L 38◦C (32◦C) LLC-MK2 Skiadopoulos et al. (1998)
HPIV1 rHPIV1 L:F456L L 38◦C (32◦C) LLC-MK2 Newman et al. (2004)
BPIV3 rBPIV L:I1103V L 40◦C (37◦C) Vero Haller et al. (2001)
Family Orthomyxoviridae
Genus Influenza virus A Flu A MDV-A NP, PB1, PB2 39◦C (33◦C) MDCK Jin et al. (2003)
Genus Influenza virus B Flu B MDV-B M1, NP, PA 37◦C (33◦C) MDCK or PCK Hoffmann et al. (2005)
Family Rhabdoviridae
Genus Vesiculovirus VSV Indiana ts11, 13,
114, 22, 33, 41, 45
L (ts114) 38.5◦C (31◦C) L Rettenmier et al. (1975)
Family Picornaviridae
Genus Enterovirus PV Sabin Type3 VP3 40◦C (35◦C) Hep-2c Minor et al. (1989)
Sabin Type2 5′-UTR 39.9◦C (35◦C) Hep-2c Macadam et al. (1991)
5′-UTR 38.4◦C (35◦C) BGM
5′-UTR 38.3◦C (35◦C) Vero F
Sabin Type1 VP1, VP3, VP4,
3Dpol , 3′-UTR
40◦C (37◦C) HeLa S3 Bouchard et al. (1995)
EV A EV71 (BrCr-ts) VP1 39◦C (36◦C) Vero Arita et al. (2005)
Family Flaviviridae
Genus Flavivirus DENV rDEN4 NS5
E645A-K646A
NS5 39◦C (35◦C) Vero Hanley et al. (2002)
Not ts HuH-7
WNV rWNV NS4B
C102S
NS4B 41◦C (37◦C) Vero Wicker et al. (2006)
JEV M1/311 ts104 Unknown 39◦C (35◦C) CF Halle and Zebovitz (1977)
LGV E5-104 NS3, E 37◦C (32◦C) Vero Rumyantsev et al. (2006)
RVFV, Rift Valley fever virus; UUKV, Uukuniemi virus; MAGV, Maguari virus; LACV, La Crosse virus; BUNV, Bunyamwera virus; SSHV, Snowshow hare virus; AKV, Akabane
virus; RSV, Respiratory syncytial virus; HPIV, Human parainfluenza virus; VSV, Vesicular stomatitis virus; PV, Poliovirus; EV, Enterovirus; DENV, Dengue virus; WNV, West
Nile virus; JEV, Japanese encephalitis virus; LGV, Langat virus.
The live-attenuated FluMist vaccine consists of master donor
virus for inﬂuenza virus A (MDV-A) and inﬂuenza virus B
(MDV-B). MDV-A has been developed by serial passages of the
wt A/Ann Arbor/6/60 strain in primary chicken kidney tissue
culture at successively low temperatures down to 25◦C (Jin et al.,
2003). MDV-A encodes ﬁve ts mutations in NP, PB1, and PB2.
A study showed that the MDV-A virus has an impaired synthesis
of anti-viral-sense genomic RNA, but not mRNA, at 39◦C (Chan
et al., 2008). MDV-A also decreases the nuclear export of RNP
and the incorporation of the M1 protein into virions at 39◦C.
Furthermore, MDV-A virions become heterogeneous in size and
shape at 39◦C. Meanwhile, MDV-B is derived from a cold-
adapted B/Ann Arbor/a/66 strain, and encodes ts mutations in
the PA and NP segments (Hoﬀmann et al., 2005).
Temperature-sensitive mutants have been successfully
developed as licensed vaccines, or candidate vaccines, in
particular, for respiratory diseases: e.g., FluMist (inﬂuenza
A and B viruses), FluAvert (equine inﬂuenza virus)
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(Paillot et al., 2006), and MEDI-559 (recombinant human
RSV A2 cp248/404/1030/SH) (Empey et al., 2010). Most ts
mutants have been identiﬁed by random mutagenesis. Rational
design of ts mutations by reverse genetics will require further
understanding of temperature-susceptible domains.
Efficacy of MP-12 Vaccine against
Aerosol Challenge of Pathogenic RVFV
A vaccine protection from an exposure via aerosols or powders
must be considered in the case of bioterrorism. Little is known
about the eﬃcacy of RVF vaccines against aerosol challenge of
pathogenic RVFV. Eﬃcacy of the MP-12 vaccine in a pathogenic
RVFV challenge via the respiratory route has been studied.
Aerosol (∼1 × 105 pfu) or intranasal vaccination (∼1 × 104 pfu
in 1.0 ml volume) of rhesus macaques withMP-12 induced serum
neutralizing IgG (Morrill and Peters, 2011a). Intramuscular
vaccination of rhesus macaques with MP-12 vaccine also led to
neutralizing antibody titers of 1:320 to 1:1,280 (Plaque Reduction
Neutralization Test 80: PRNT80), which was maintained for
6 years. The vaccinated rhesus macaques were protected from
an aerosol challenge of the pathogenic ZH501 strain (Morrill
and Peters, 2011b). These results clearly indicate that the MP-
12 vaccine is eﬃcacious for aerosol RVFV challenge, regardless
of vaccination routes. Meanwhile, further characterization of
viral replications in upper and lower respiratory tract will be
important to evaluate the risk of available live-attenuated RVF
vaccine candidates: e.g., MP-12, or rMP12-NSm21/384 (Morrill
et al., 2013a,b), Clone 13 vaccine (Dungu et al., 2010), or
rZH501NSsNSm (Bird et al., 2011).
Concluding Remarks
Outbreak of RVF causes decreased animal productivities and viral
persistence in mosquito vectors for unknown periods of time,
thus signiﬁcantly impacting the animal industry. In the U.S.,
the live-attenuated MP-12 vaccine is conditionally licensed, but
the vaccine will still require an improvement in terms of safety
considering reported side eﬀects: e.g., abortions in pregnant ewes,
necrosis in calf liver. Further studies should design additional
attenuation mutations rationally, including gene deletion(s) or ts
mutations, to fully attenuate the S-, M-, and L-segments, toward
the development of highly safe and eﬃcacious RVF vaccines
(Grobbelaar et al., 2011; Ikegami, 2012; Lihoradova and Ikegami,
2012).
Acknowledgments
We thank Ms. Hoai J. Ly and Ms. Inaia Phoenix for their
proofreading of this manuscript. This work was partly supported
by NIH grant R01 AI08764301, and by the Sealy Center for
Vaccine Development at The University of Texas Medical Branch
at Galveston.
References
Abu-Elyazeed, R., El-Sharkawy, S., Olson, J., Botros, B., Soliman, A., Salib, A., et al.
(1996). Prevalence of anti-Rift-Valley-fever IgM antibody in abattoir workers in
the Nile delta during the 1993 outbreak in Egypt. Bull. World Health Organ. 74,
155–158.
Arita, M., Shimizu, H., Nagata, N., Ami, Y., Suzaki, Y., Sata, T., et al.
(2005). Temperature-sensitive mutants of enterovirus 71 show attenuation
in cynomolgus monkeys. J. Gen. Virol. 86, 1391–1401. doi: 10.1099/vir.0.8
07840
Billecocq, A., Spiegel, M., Vialat, P., Kohl, A., Weber, F., Bouloy, M., et al. (2004).
NSs protein of Rift Valley fever virus blocks interferon production by inhibiting
host gene transcription. J. Virol. 78, 9798–9806. doi: 10.1128/JVI.78.18.9798-
9806.2004
Bird, B. H., Ksiazek, T. G., Nichol, S. T., and Maclachlan, N. J. (2009). Rift
Valley fever virus. J. Am. Vet. Med. Assoc. 234, 883–893. doi: 10.2460/javma.2
34.7.883
Bird, B. H., Maartens, L. H., Campbell, S., Erasmus, B. J., Erickson, B. R., Dodd,
K. A., et al. (2011). Rift Valley fever virus vaccine lacking the NSs and NSm
genes is safe, nonteratogenic, and confers protection from viremia, pyrexia,
and abortion following challenge in adult and pregnant sheep. J. Virol. 85,
12901–12909. doi: 10.1128/JVI.06046-11
Botros, B., Omar, A., Elian, K., Mohamed, G., Soliman, A., Salib, A., et al.
(2006). Adverse response of non-indigenous cattle of European breeds to live
attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 78, 787–791. doi:
10.1002/jmv.20624
Bouchard, M. J., Lam, D. H., and Racaniello, V. R. (1995). Determinants of
attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.
J. Virol. 69, 4972–4978.
Caplen, H., Peters, C. J., and Bishop, D. H. (1985). Mutagen-directed attenuation
of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol.
66(Pt 10), 2271–2277. doi: 10.1099/0022-1317-66-10-2271
CDC. (2007). Rift Valley fever outbreak–Kenya, November 2006-January 2007.
MMWRMorb. Mortal. Wkly. Rep. 56, 73–76.
Chambers, P. G., and Swanepoel, R. (1980). Rift valley fever in abattoir workers.
Cent. Afr. J. Med. 26, 122–126.
Chan, W., Zhou, H., Kemble, G., and Jin, H. (2008). The cold adapted
and temperature sensitive inﬂuenza A/Ann Arbor/6/60 virus, the master
donor virus for live attenuated inﬂuenza vaccines, has multiple defects
in replication at the restrictive temperature. Virology 380, 304–311. doi:
10.1016/j.virol.2008.07.027
Crabtree, M. B., Kent Crockett, R. J., Bird, B. H., Nichol, S. T., Erickson, B. R.,
Biggerstaﬀ, B. J., et al. (2012). Infection and transmission of Rift Valley
fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential
role for NSm in mosquito infection. PLoS Negl. Trop. Dis. 6:e1639. doi:
10.1371/journal.pntd.0001639
Daubney, R., and Hudson, J. R. (1931). Enzootic hepatitis or Rift Valley fever: an
undescribed virus disease of sheep cattle and man from east Africa. J. Pathol.
Bacteriol. 34, 545–579. doi: 10.1002/path.1700340418
Dungu, B., Louw, I., Lubisi, A., Hunter, P., Von Teichman, B. F., and Bouloy, M.
(2010). Evaluation of the eﬃcacy and safety of the Rift Valley Fever Clone 13
vaccine in sheep. Vaccine 28, 4581–4587. doi: 10.1016/j.vaccine.2010.04.085
Eifan, S. A., and Elliott, R. M. (2009). Mutational analysis of the Bunyamwera
Orthobunyavirus nucleocapsid protein gene. J. Virol. 83, 11307–11317. doi:
10.1128/JVI.01460-09
Empey, K. M., Peebles, R. S. Jr., and Kolls, J. K. (2010). Pharmacologic advances in
the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50,
1258–1267. doi: 10.1086/651603
Endres, M. J., Valsamakis, A., Gonzalez-Scarano, F., and Nathanson, N.
(1990). Neuroattenuated bunyavirus variant: derivation, characterization, and
revertant clones. J. Virol. 64, 1927–1933.
Gahmberg, N. (1984). Characterization of two recombination-complementation
groups of Uukuniemi virus temperature-sensitive mutants. J. Gen. Virol.
65(Pt 6), 1079–1090. doi: 10.1099/0022-1317-65-6-1079
Frontiers in Microbiology | www.frontiersin.org 6 August 2015 | Volume 6 | Article 787
Nishiyama and Ikegami Temperature-sensitivity and RVF vaccine development
Galloway, S. E., and Wertz, G. W. (2009). A temperature sensitive VSV identiﬁes
L protein residues that aﬀect transcription but not replication. Virology 388,
286–293. doi: 10.1016/j.virol.2009.03.015
Gentsch, J., and Bishop, D. H. (1976). Recombination and complementation
between temperature-sensitive mutants of a Bunyavirus, snowshoe hare virus.
J. Virol. 20, 351–354.
Gerrard, S. R., and Nichol, S. T. (2002). Characterization of the Golgi retention
motif of Rift Valley fever virus G(N) glycoprotein. J. Virol. 76, 12200–12210.
doi: 10.1128/JVI.76.23.12200-12210.2002
Gommet, C., Billecocq, A., Jouvion, G., Hasan, M., Zaverucha Do Valle, T.,
Guillemot, L., et al. (2011). Tissue tropism and target cells of NSs-deleted rift
valley fever virus in live immunodeﬁcient mice. PLoS Negl. Trop. Dis. 5:e1421.
doi: 10.1371/journal.pntd.0001421
Grobbelaar, A. A., Weyer, J., Leman, P. A., Kemp, A., Paweska, J. T., and
Swanepoel, R. (2011). Molecular epidemiology of Rift Valley fever virus. Emerg.
Infect. Dis. 17, 2270–2276. doi: 10.3201/eid1712.111035
Habjan, M., Pichlmair, A., Elliott, R. M., Overby, A. K., Glatter, T., Gstaiger, M.,
et al. (2009). NSs protein of rift valley fever virus induces the speciﬁc
degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 83,
4365–4375. doi: 10.1128/JVI.02148-08
Halle, S., and Zebovitz, E. (1977). A spontaneous temperature sensitive mutant
of Japanese encephalitis virus: preliminary characterization. Arch. Virol. 54,
165–176. doi: 10.1007/BF01314783
Haller, A. A., Macphail, M., Mitiku, M., and Tang, R. S. (2001). A single amino
acid substitution in the viral polymerase creates a temperature-sensitive and
attenuated recombinant bovine parainﬂuenza virus type 3. Virology 288, 342–
350. doi: 10.1006/viro.2001.1106
Hanley, K. A., Lee, J. J., Blaney, J. E. Jr., Murphy, B. R., and Whitehead,
S. S. (2002). Paired charge-to-alanine mutagenesis of dengue virus type 4
NS5 generates mutants with temperature-sensitive, host range, and mouse
attenuation phenotypes. J. Virol. 76, 525–531. doi: 10.1128/JVI.76.2.525-
531.2002
Harmon, B., Schudel, B. R., Maar, D., Kozina, C., Ikegami, T., Tseng, C. T.,
et al. (2012). Rift Valley fever virus strain MP-12 enters mammalian host
cells via caveolae-mediated endocytosis. J. Virol. 86, 12954–12970. doi:
10.1128/JVI.02242-12
Hoﬀmann, E., Mahmood, K., Chen, Z., Yang, C. F., Spaete, J., Greenberg, H. B.,
et al. (2005). Multiple gene segments control the temperature sensitivity and
attenuation phenotypes of ca B/Ann Arbor/1/66. J. Virol. 79, 11014–11021. doi:
10.1128/JVI.79.17.11014-11021.2005
Hunter, P., Erasmus, B. J., and Vorster, J. H. (2002). Teratogenicity of a
mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet.
Res. 69, 95–98.
Ikegami, T. (2012). Molecular biology and genetic diversity of Rift Valley
fever virus. Antiviral Res. 95, 293–310. doi: 10.1016/j.antiviral.2012.
106.001
Ikegami, T., Hill, T. E., Smith, J. K., Zhang, L., Juelich, T. L., Gong, B., et al. (2015).
Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of
partial attenuations in the S-, M- and L-segments. J. Virol. 89, 7262–7276. doi:
10.1128/JVI.00135-15
Ikegami, T., and Makino, S. (2009). Rift valley fever vaccines. Vaccine 27(Suppl. 4),
D69–D72. doi: 10.1016/j.vaccine.2009.07.046
Ikegami, T., and Makino, S. (2011). The pathogenesis of rift valley fever. Viruses 3,
493–519. doi: 10.3390/v3050493
Ikegami, T., Narayanan, K., Won, S., Kamitani, W., Peters, C. J., and Makino, S.
(2009). Rift Valley fever virus NSs protein promotes post-transcriptional
downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.
PLoS Pathog. 5:e1000287. doi: 10.1371/journal.ppat.1000287
Jin, H., Lu, B., Zhou, H., Ma, C., Zhao, J., Yang, C. F., et al. (2003). Multiple amino
acid residues confer temperature sensitivity to human inﬂuenza virus vaccine
strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306,
18–24. doi: 10.1016/S0042-6822(02)00035-1
Kading, R. C., Crabtree, M. B., Bird, B. H., Nichol, S. T., Erickson, B. R.,
Horiuchi, K., et al. (2014). Deletion of the NSm virulence gene of Rift
Valley fever virus inhibits virus replication in and dissemination from the
midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 8:e2670. doi:
10.1371/journal.pntd.0002670
Kainulainen, M., Habjan, M., Hubel, P., Busch, L., Lau, S., Colinge, J., et al. (2014).
Virulence factor NSs of rift valley fever virus recruits the F-box protein FBXO3
to degrade subunit p62 of general transcription factor TFIIH. J. Virol. 88,
3464–3473. doi: 10.1128/JVI.02914-13
Kalveram, B., Lihoradova, O., and Ikegami, T. (2011). NSs protein of rift valley
fever virus promotes post-translational downregulation of the TFIIH subunit
p62. J. Virol. 85, 6234–6243. doi: 10.1128/JVI.02255-10
Kreher, F., Tamietti, C., Gommet, C., Guillemot, L., Ermonval, M., Failloux, A. B.,
et al. (2014). The Rift Valley fever accessory proteins NSm and P78/NSm-Gn are
determinants of virus propagation in vertebrate and invertebrate hosts. Emerg.
Microbe Infect. 3, e71. doi: 10.1038/emi.2014.71
Le May, N., Dubaele, S., Proietti De Santis, L., Billecocq, A., Bouloy, M., and Egly,
J. M. (2004). TFIIH transcription factor, a target for the Rift Valley hemorrhagic
fever virus. Cell 116, 541–550. doi: 10.1016/S0092-8674(04)00132-1
Le May, N., Mansuroglu, Z., Leger, P., Josse, T., Blot, G., Billecocq, A., et al.
(2008). A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus
infected cells. PLoS Pathog. 4:e13. doi: 10.1371/journal.ppat.0040013
Lihoradova, O., and Ikegami, T. (2012). Modifying the NSs gene to improve live-
attenuated vaccine for Rift Valley fever. Expert Rev. Vaccines 11, 1283–1285. doi:
10.1586/erv.12.106
Lozach, P. Y., Kuhbacher, A., Meier, R., Mancini, R., Bitto, D., Bouloy, M., et al.
(2011). DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10, 75–88.
doi: 10.1016/j.chom.2011.06.007
Macadam, A. J., Pollard, S. R., Ferguson, G., Dunn, G., Skuce, R., Almond, J. W.,
et al. (1991). The 5’ noncoding region of the type 2 poliovirus vaccine strain
contains determinants of attenuation and temperature sensitivity.Virology 181,
451–458. doi: 10.1016/0042-6822(91)90877-E
Madani, T. A., Al-Mazrou, Y. Y., Al-Jeﬀri, M. H., Mishkhas, A. A., Al-Rabeah,
A.M., Turkistani, A. M., et al. (2003). Rift Valley fever epidemic in Saudi Arabia:
epidemiological, clinical, and laboratory characteristics. Clin. Infect. Dis. 37,
1084–1092. doi: 10.1086/378747
Miller, M. M., Bennett, K. E., Drolet, B. S., Lindsay, R., Mecham, J. O., Reeves,
W. K., et al. (2015). Evaluation of the eﬃcacy, potential for vector transmission,
and duration of immunity of MP-12, an attenuated Rift Valley fever virus
vaccine candidate, in sheep.Clin. Vaccine Immunol. doi: 10.1128/CVI.00114-15
[Epub ahead of print].
Minor, P. D., Dunn, G., Evans, D. M., Magrath, D. I., John, A., Howlett, J.,
et al. (1989). The temperature sensitivity of the Sabin type 3 vaccine strain
of poliovirus: molecular and structural eﬀects of a mutation in the capsid
protein VP3. J. Gen. Virol. 70(Pt 5), 1117–1123. doi: 10.1099/0022-1317-70-
5-1117
Morrill, J. C., Carpenter, L., Taylor, D., Ramsburg, H.H., Quance, J., and Peters, C. J.
(1991). Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in
sheep. Vaccine 9, 35–41. doi: 10.1016/0264-410X(91)90314-V
Morrill, J. C., Jennings, G. B., Caplen, H., Turell, M. J., Johnson, A. J., and
Peters, C. J. (1987). Pathogenicity and immunogenicity of amutagen-attenuated
Rift Valley fever virus immunogen in pregnant ewes. Am. J. Vet. Res. 48,
1042–1047.
Morrill, J. C., Laughlin, R. C., Lokugamage, N., Pugh, R., Sbrana, E., Weise,
W. J., et al. (2013a). Safety and immunogenicity of recombinant Rift
Valley fever MP-12 vaccine candidates in sheep. Vaccine 31, 559–565. doi:
10.1016/j.vaccine.2012.10.118
Morrill, J. C., Laughlin, R. C., Lokugamage, N., Wu, J., Pugh, R., Kanani, P.,
et al. (2013b). Immunogenicity of a recombinant Rift Valley fever MP-
12-NSm deletion vaccine candidate in calves. Vaccine 31, 4988–4994. doi:
10.1016/j.vaccine.2013.08.003
Morrill, J. C., Mebus, C. A., and Peters, C. J. (1997a). Safety and eﬃcacy of a
mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res. 58,
1104–1109.
Morrill, J. C., Mebus, C. A., and Peters, C. J. (1997b). Safety of a mutagen-
attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am. J.
Vet. Res. 58, 1110–1114.
Morrill, J. C., and Peters, C. J. (2003). Pathogenicity and neurovirulence of a
mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 21,
2994–3002. doi: 10.1016/S0264-410X(03)00131-2
Morrill, J. C., and Peters, C. J. (2011a). Mucosal immunization of rhesus macaques
with Rift Valley Fever MP-12 vaccine. J. Infect. Dis. 204, 617–625. doi:
10.1093/infdis/jir354
Morrill, J. C., and Peters, C. J. (2011b). Protection of MP-12-vaccinated rhesus
macaques against parenteral and aerosol challenge with virulent rift valley fever
virus. J. Infect. Dis. 204, 229–236. doi: 10.1093/infdis/jir249
Frontiers in Microbiology | www.frontiersin.org 7 August 2015 | Volume 6 | Article 787
Nishiyama and Ikegami Temperature-sensitivity and RVF vaccine development
Muller, R., Poch, O., Delarue, M., Bishop, D. H., and Bouloy, M. (1994). Rift Valley
fever virus L segment: correction of the sequence and possible functional role
of newly identiﬁed regions conserved in RNA-dependent polymerases. J. Gen.
Virol. 75, 1345–1352. doi: 10.1099/0022-1317-75-6-1345
Newman, J. T., Riggs, J. M., Surman, S. R., Mcauliﬀe, J. M., Mulaikal, T. A., Collins,
P. L., et al. (2004). Generation of recombinant human parainﬂuenza virus type
1 vaccine candidates by importation of temperature-sensitive and attenuating
mutations from heterologous paramyxoviruses. J. Virol. 78, 2017–2028. doi:
10.1128/JVI.78.4.2017-2028.2004
Ogawa, Y., Kato, K., Tohya, Y., and Akashi, H. (2007). Characterization
of temperature-sensitive Akabane virus mutants and their roles in
attenuation. Arch. Virol. 152, 1679–1686. doi: 10.1007/s00705-007-
0991-4
Olaleye, O. D., Tomori, O., Ladipo, M. A., and Schmitz, H. (1996). Rift Valley fever
in Nigeria: infections in humans. Rev. Sci. Tech. 15, 923–935.
Paillot, R., Hannant, D., Kydd, J. H., and Daly, J. M. (2006). Vaccination
against equine inﬂuenza: quid novi? Vaccine 24, 4047–4061. doi:
10.1016/j.vaccine.2006.02.030
Pepin, M., Bouloy, M., Bird, B. H., Kemp, A., and Paweska, J. (2010). Rift
Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis,
molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41, 61.
doi: 10.1051/vetres/2010033 v100009
Piper, M. E., Sorenson, D. R., and Gerrard, S. R. (2011). Eﬃcient cellular release
of Rift Valley fever virus requires genomic RNA. PLoS ONE 6:e18070. doi:
10.1371/journal.pone.0018070
Polack, F. P., and Karron, R. A. (2004). The future of respiratory syncytial
virus vaccine development. Pediatr. Infect. Dis. J. 23, S65–S73. doi:
10.1097/01.inf.0000108194.71892.95
Pollitt, E., Zhao, J., Muscat, P., and Elliott, R. M. (2006). Characterization of
Maguari orthobunyavirus mutants suggests the nonstructural protein NSm
is not essential for growth in tissue culture. Virology 348, 224–232. doi:
10.1016/j.virol.2005.12.026
Rahmeh, A. A., Schenk, A. D., Danek, E. I., Kranzusch, P. J., Liang, B.,
Walz, T., et al. (2010). Molecular architecture of the vesicular stomatitis
virus RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 107, 20075–20080. doi:
10.1073/pnas.1013559107
Reguera, J., Weber, F., and Cusack, S. (2010). Bunyaviridae RNA polymerases
(L-protein) have an N-terminal, inﬂuenza-like endonuclease domain,
essential for viral cap-dependent transcription. PLoS Pathog. 6:e1001101.
doi: 10.1371/journal.ppat.1001101
Rettenmier, C. W., Dumont, R., and Baltimore, D. (1975). Screening procedure for
complementation-dependent mutants of vesicular stomatitis virus. J. Virol. 15,
41–49.
Richman, D. D., and Murphy, B. R. (1979). The association of the temperature-
sensitive phenotype with viral attenuation in animals and humans: implications
for the development and use of live virus vaccines. Rev. Infect. Dis. 1, 413–433.
doi: 10.1093/clinids/1.3.413
Robertshaw, D. (2004). “Temperature regulation and thermal environment,” in
Duke’s Physiology of Domestic Animals, 12th Edn, ed. W. O. Reece (Ithaca, NY:
Cornell University Press).
Rossi, C. A., and Turell, M. J. (1988). Characterization of attenuated strains of Rift
Valley fever virus. J. Gen. Virol. 69(Pt 4), 817–823. doi: 10.1099/0022-1317-69-
4-817
Rumyantsev, A. A., Murphy, B. R., and Pletnev, A. G. (2006). A tick-borne
Langat virus mutant that is temperature sensitive and host range restricted
in neuroblastoma cells and lacks neuroinvasiveness for immunodeﬁcient mice.
J. Virol. 80, 1427–1439. doi: 10.1128/JVI.80.3.1427-1439.2006
Saluzzo, J. F., and Smith, J. F. (1990). Use of reassortant viruses to map attenuating
and temperature-sensitive mutations of the Rift Valley fever virus MP-12
vaccine. Vaccine 8, 369–375. doi: 10.1016/0264-410X(90)90096-5
Schmaljohn, C., andNichol, S.T. (2007). “Bunyaviridae,” in Fields Virology, 5th Edn,
eds D. M. Knipe, P. M. Howley, D. E. Griﬃn, R. A. Lamb, M. A. Martin, B.
Roizman, et al. (Philadelphia, PA: Lippincott, Williams &Wilkins), 1741–1789.
Skiadopoulos, M. H., Durbin, A. P., Tatem, J. M., Wu, S. L., Paschalis, M., Tao,
T., et al. (1998). Three amino acid substitutions in the L protein of the human
parainﬂuenza virus type 3 cp45 live attenuated vaccine candidate contribute to
its temperature-sensitive and attenuation phenotypes. J. Virol. 72, 1762–1768.
Smith, D. R., Steele, K. E., Shamblin, J., Honko, A., Johnson, J., Reed, C., et al.
(2010). The pathogenesis of Rift Valley fever virus in the mouse model.Virology
407, 256–267. doi: 10.1016/j.virol.2010.08.016
Swanepoel, R., and Coetzer, J. A.W. (2004). “Rift Valley fever,” in Infectious Diseases
of Livestock with Special Reference to Southern Africa, 2nd edn, eds J. A. W.
Coetzer and R. C. Tustin (Cape Town: Oxford University Press), 1037–1070.
Talan, M. (1984). Body temperature of C57BL/6J mice with age. Exp. Gerontol. 19,
25–29. doi: 10.1016/0531-5565(84)90028-7
Tang, R. S., Nguyen, N., Zhou, H., and Jin, H. (2002). Clustered charge-to-
alanine mutagenesis of human respiratory syncytial virus L polymerase
generates temperature-sensitive viruses. Virology 302, 207–216. doi:
10.1006/viro.2002.1596
Terasaki, K., Won, S., and Makino, S. (2013). The C-terminal region of Rift
Valley fever virus NSm protein targets the protein to the mitochondrial outer
membrane and exerts anti-apoptotic function. J. Virol. 87, 676–682. doi:
10.1128/JVI.02192-12
Vialat, P., Muller, R., Vu, T. H., Prehaud, C., and Bouloy, M. (1997). Mapping of
the mutations present in the genome of the Rift Valley fever virus attenuated
MP12 strain and their putative role in attenuation. Virus Res. 52, 43–50. doi:
10.1016/S0168-1702(97)00097-X
Weingartl, H. M., Zhang, S., Marszal, P., Mcgreevy, A., Burton, L., and Wilson,
W. C. (2014). Rift Valley fever virus incorporates the 78 kDa glycoprotein
into virions matured in mosquito C6/36 cells. PLoS ONE 9:e87385. doi:
10.1371/journal.pone.0087385
Whitehead, S. S., Firestone, C. Y., Collins, P. L., and Murphy, B. R. (1998).
A single nucleotide substitution in the transcription start signal of the M2
gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major
determinant of the temperature-sensitive and attenuation phenotypes. Virology
247, 232–239. doi: 10.1006/viro.1998.9248
Wicker, J. A., Whiteman, M. C., Beasley, D. W., Davis, C. T., Zhang, S., Schneider,
B. S., et al. (2006). A single amino acid substitution in the central portion of the
West Nile virus NS4B protein confers a highly attenuated phenotype in mice.
Virology 349, 245–253. doi: 10.1016/j.virol.2006.03.007
Won, S., Ikegami, T., Peters, C. J., and Makino, S. (2006). NSm and 78-kilodalton
proteins of Rift Valley fever virus are nonessential for viral replication in cell
culture. J. Virol. 80, 8274–8278. doi: 10.1128/JVI.00476-06
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Nishiyama and Ikegami. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 8 August 2015 | Volume 6 | Article 787
